Find

Department of Clinical Medicine

Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. / Sleutjes, Boudewijn T.H.M.; Bystrup Jacobsen, Anna ; Tankisi, Hatice et al.
I: Clinical Neurophysiology, Bind 132, Nr. 12, 12.2021, s. 3152-3159.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Sleutjes, BTHM, Bystrup Jacobsen, A , Tankisi, H, Gorkem Sirin, N, Emre Oge, A, Henderson, RD, van Doorn, PA, van den Berg, LH & van Eijk, RPA 2021, 'Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan', Clinical Neurophysiology, bind 132, nr. 12, s. 3152-3159. https://doi.org/10.1016/j.clinph.2021.09.014

APA

Sleutjes, B. T. H. M., Bystrup Jacobsen, A., Tankisi, H., Gorkem Sirin, N., Emre Oge, A., Henderson, R. D., van Doorn, P. A., van den Berg, L. H., & van Eijk, R. P. A. (2021). Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clinical Neurophysiology, 132(12), 3152-3159. https://doi.org/10.1016/j.clinph.2021.09.014

CBE

Sleutjes BTHM, Bystrup Jacobsen A , Tankisi H, Gorkem Sirin N, Emre Oge A, Henderson RD, van Doorn PA, van den Berg LH, van Eijk RPA. 2021. Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clinical Neurophysiology. 132(12):3152-3159. https://doi.org/10.1016/j.clinph.2021.09.014

MLA

Sleutjes, Boudewijn T.H.M. et al. "Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan". Clinical Neurophysiology. 2021, 132(12). 3152-3159. https://doi.org/10.1016/j.clinph.2021.09.014

Vancouver

Sleutjes BTHM, Bystrup Jacobsen A , Tankisi H, Gorkem Sirin N, Emre Oge A, Henderson RD et al. Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clinical Neurophysiology. 2021 dec.;132(12):3152-3159. doi: 10.1016/j.clinph.2021.09.014

Author

Sleutjes, Boudewijn T.H.M. ; Bystrup Jacobsen, Anna ; Tankisi, Hatice et al. / Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. I: Clinical Neurophysiology. 2021 ; Bind 132, Nr. 12. s. 3152-3159.

Bibtex

@article{5c6a77b0d3dc48d6a2b8fd990bf81be9,

title = "Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan",

abstract = "Objective: To determine which compound muscle action potential (CMAP) scan-derived electrophysiological markers are most sensitive for monitoring disease progression in amyotrophic lateral sclerosis (ALS), and whether they hold value for clinical trials. Methods: We used four independent patient cohorts to assess longitudinal patterns of a comprehensive set of electrophysiological markers including their association with the ALS functional rating scale (ALSFRS-R). Results were translated to trial sample size requirements. Results: In 65 patients, 225 thenar CMAP scan recordings were obtained. Electrophysiological markers showed extensive variation in their longitudinal trajectories. Expressed as standard deviations per month, motor unit number estimation (MUNE) values declined by 0.09 (CI 0.07–0.12), D50, a measure that quantifies CMAP scan discontinuities, declined by 0.09 (CI 0.06–0.13) and maximum CMAP by 0.05 (CI 0.03–0.08). ALSFRS-R declined fastest (0.12, CI 0.08 – 0.15), however the between-patient variability was larger compared to electrophysiological markers, resulting in larger sample sizes. MUNE reduced the sample size by 19.1% (n = 388 vs n = 314) for a 6-month study compared to the ALSFRS-R. Conclusions: CMAP scan-derived markers show promise in monitoring disease progression in ALS patients, where MUNE may be its most suitable derivate. Significance: MUNE may increase clinical trial efficiency compared to clinical endpoints.",

keywords = "Clinical trials, Compound muscle action potential scan, Electrophysiological markers, Monitoring disease progression, Motor unit number estimation, Motor unit sizes",

author = "Sleutjes, {Boudewijn T.H.M.} and {Bystrup Jacobsen}, Anna and Hatice Tankisi and {Gorkem Sirin}, N. and {Emre Oge}, A. and Henderson, {Robert D.} and {van Doorn}, {Pieter A.} and {van den Berg}, {Leonard H.} and {van Eijk}, {Ruben P.A.}",

note = "Publisher Copyright: {\textcopyright} 2021 International Federation of Clinical Neurophysiology",

year = "2021",

month = dec,

doi = "10.1016/j.clinph.2021.09.014",

language = "English",

volume = "132",

pages = "3152--3159",

journal = "Clinical Neurophysiology",

issn = "1388-2457",

publisher = "Elsevier Ireland Ltd.",

number = "12",

}

RIS

TY - JOUR

T1 - Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan

AU - Sleutjes, Boudewijn T.H.M.

AU - Bystrup Jacobsen, Anna

AU - Tankisi, Hatice

AU - Gorkem Sirin, N.

AU - Emre Oge, A.

AU - Henderson, Robert D.

AU - van Doorn, Pieter A.

AU - van den Berg, Leonard H.

AU - van Eijk, Ruben P.A.

PY - 2021/12

Y1 - 2021/12

N2 - Objective: To determine which compound muscle action potential (CMAP) scan-derived electrophysiological markers are most sensitive for monitoring disease progression in amyotrophic lateral sclerosis (ALS), and whether they hold value for clinical trials. Methods: We used four independent patient cohorts to assess longitudinal patterns of a comprehensive set of electrophysiological markers including their association with the ALS functional rating scale (ALSFRS-R). Results were translated to trial sample size requirements. Results: In 65 patients, 225 thenar CMAP scan recordings were obtained. Electrophysiological markers showed extensive variation in their longitudinal trajectories. Expressed as standard deviations per month, motor unit number estimation (MUNE) values declined by 0.09 (CI 0.07–0.12), D50, a measure that quantifies CMAP scan discontinuities, declined by 0.09 (CI 0.06–0.13) and maximum CMAP by 0.05 (CI 0.03–0.08). ALSFRS-R declined fastest (0.12, CI 0.08 – 0.15), however the between-patient variability was larger compared to electrophysiological markers, resulting in larger sample sizes. MUNE reduced the sample size by 19.1% (n = 388 vs n = 314) for a 6-month study compared to the ALSFRS-R. Conclusions: CMAP scan-derived markers show promise in monitoring disease progression in ALS patients, where MUNE may be its most suitable derivate. Significance: MUNE may increase clinical trial efficiency compared to clinical endpoints.

AB - Objective: To determine which compound muscle action potential (CMAP) scan-derived electrophysiological markers are most sensitive for monitoring disease progression in amyotrophic lateral sclerosis (ALS), and whether they hold value for clinical trials. Methods: We used four independent patient cohorts to assess longitudinal patterns of a comprehensive set of electrophysiological markers including their association with the ALS functional rating scale (ALSFRS-R). Results were translated to trial sample size requirements. Results: In 65 patients, 225 thenar CMAP scan recordings were obtained. Electrophysiological markers showed extensive variation in their longitudinal trajectories. Expressed as standard deviations per month, motor unit number estimation (MUNE) values declined by 0.09 (CI 0.07–0.12), D50, a measure that quantifies CMAP scan discontinuities, declined by 0.09 (CI 0.06–0.13) and maximum CMAP by 0.05 (CI 0.03–0.08). ALSFRS-R declined fastest (0.12, CI 0.08 – 0.15), however the between-patient variability was larger compared to electrophysiological markers, resulting in larger sample sizes. MUNE reduced the sample size by 19.1% (n = 388 vs n = 314) for a 6-month study compared to the ALSFRS-R. Conclusions: CMAP scan-derived markers show promise in monitoring disease progression in ALS patients, where MUNE may be its most suitable derivate. Significance: MUNE may increase clinical trial efficiency compared to clinical endpoints.

KW - Clinical trials

KW - Compound muscle action potential scan

KW - Electrophysiological markers

KW - Monitoring disease progression

KW - Motor unit number estimation

KW - Motor unit sizes

UR - http://www.scopus.com/inward/record.url?scp=85118567554&partnerID=8YFLogxK

U2 - 10.1016/j.clinph.2021.09.014

DO - 10.1016/j.clinph.2021.09.014

M3 - Journal article

C2 - 34749234

AN - SCOPUS:85118567554

VL - 132

SP - 3152

EP - 3159

JO - Clinical Neurophysiology

JF - Clinical Neurophysiology

SN - 1388-2457

IS - 12

ER -